Elucidating essential kinases of endothelin signalling by logic modelling of phosphoproteomics data
OPEN ACCESS
Author / Producer
Date
2019-08-01
Publication Type
Journal Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
Endothelins (EDN) are peptide hormones that activate a GPCR signalling system and contribute to several diseases, including hypertension and cancer. Current knowledge about EDN signalling is fragmentary, and no systems level understanding is available. We investigated phosphoproteomic changes caused by endothelin B receptor (ENDRB) activation in the melanoma cell lines UACC257 and A2058 and built an integrated model of EDNRB signalling from the phosphoproteomics data. More than 5,000 unique phosphopeptides were quantified. EDN induced quantitative changes in more than 800 phosphopeptides, which were all strictly dependent on EDNRB. Activated kinases were identified based on high confidence EDN target sites and validated by Western blot. The data were combined with prior knowledge to construct the first comprehensive logic model of EDN signalling. Among the kinases predicted by the signalling model, AKT, JNK, PKC and AMP could be functionally linked to EDN‐induced cell migration. The model contributes to the system‐level understanding of the mechanisms underlying the pleiotropic effects of EDN signalling and supports the rational selection of kinase inhibitors for combination treatments with EDN receptor antagonists.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
15 (8)
Pages / Article No.
Publisher
EMBO Press
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Endothelin; GPCR; Melanoma; Molecular modelling; Phosphoproteomics
Organisational unit
03663 - Aebersold, Rudolf (emeritus) / Aebersold, Rudolf (emeritus)
Notes
Funding
670821 - Proteomics 4D: The proteome in context (EC)
115766 - Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery (EC)
115766 - Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery (EC)